TrialCancer immunology, immunotherapy : CII2025

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial.

Ying Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.